The abstract is read at the publisher; the summary is JClub's.
A modified Delphi consensus in primary biliary cholangitis (PBC) reached agreement on 16 statements and 42 recommendations, with 62 international panelists and 88% then 60% voting response rates.
- Why it matters: Regulatory acceptance of liver biochemistry and non-invasive fibrosis measures as validated efficacy endpoints is limited, real-world evidence is not well integrated, and patient-reported outcomes lack harmonized use.
- What they did: EASL and AASLD convened a multi-stakeholder panel of 62 panellists across three working groups, using online meetings, one in-person conference, and two Delphi voting rounds to review evidence and define a regulatory-aligned framework.
- The result: The consensus recommendations create a comprehensive, pragmatic framework to support and expand the regulatory pathway for developing and approving new PBC therapies.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.